Pharming to Present at Acumen BioFin Rodman & Renshaw Healthcare
Conference
Leiden, The Netherlands, November 1, 2007. Biotech company Pharming
Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that it
will present at the Acumen BioFin Rodman & Renshaw Healthcare
Conference (November 5-7, 2007) in New York.
Dr. Francis Pinto, Chief Executive Officer of Pharming, will present
on Wednesday, November 7 at 1:40 pm Eastern Time. The presentation
will be available on Pharming's website after the meeting.
The conference attendees include institutional investors from the
United States and Europe. For further information on the Acumen
BioFin Rodman & Renshaw Healthcare Conference, please visit
www.rodmanandrenshaw.com/conferences.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment
of genetic disorders, ageing diseases, specialty products for
surgical indications, intermediates for various applications and
nutritional products. Pharming has two products in late stage
development - Rhucin® (recombinant human C1 inhibitor) for hereditary
angioedema (MAA under review by EMEA) and human lactoferrin for use
in food products (GRAS notification under review by FDA). The
advanced technologies of the Company include innovative platforms for
the production of protein therapeutics, technology and processes for
the purification and formulation of these products, as well as
technologies in the field of tissue repair (via its collaboration
with Novathera) and DNA repair (via its acquisition of DNage).
Additional information is available on the Pharming website,
www.pharming.com and on www.dnage.nl.
This press release contains forward looking statements that involve
known and unknown risks, uncertainties and other factors, which may
cause the actual results, performance or achievements of the Company
to be materially different from the results, performance or
achievements expressed or implied by these forward looking
statements. The press release also appears in Dutch. In the event of
any inconsistency, the English version will prevail over the Dutch
version.
Contact:
Carina Hamaker Julia Philips
Investor Voice Financial Dynamics
T: +31 (0)6 537 499 59 T: +44 (0)20 7269 7187
T: +31 (0)71 52 47 400 T: +44 (0)7747 602 739
Rein Strijker Samir Singh
Pharming Group NV Pharming Group NV
T: +31 (0)71 52 47 400 T: +1 908 720 6224
